

# HLDA9 ANTIBODY VALIDATION FILE

## ANTIBODY INFORMATION

**Antibody Name:** E9

**Specificity:** CD307a, Human FCRL1

**Antibody species:** Mouse

**Ig Isotype:** IgG1 (kappa)

**Immunogen:** DNA-immunization followed by a boost with the FCRL1 transfected cells.

**Epitope recognized:** Topographical epitope III in the extracellular domain.

**Submitter:** Satoshi Nagata and Ira Pastan (Sanford Research/USD).


## INFORMATION FOR CONFIRMATION OF SPECIFICITY:

Expression on transfected COS: positive. (Fig. 1A)

Expression on the cell- surface of cell line: positive with Burkitt lymphoma B cell line Rec-1.  
(Fig. 1B)

Expression on cell- surface of normal cell: positive with tonsil cells. (Fig. 1C)

**Figure 1**



Reactivity of CD307a with cell lines

	Cell lines	CD307a
EBV-transformed B cells	CESS	+
Burkitt lymphoma B cell lines	Raji	-
	Daudi	-
	Namalwa	-
	Ramos	+++
	Rec-1	++++
Multiple myeloma	RPMI8226	-
T cell leukemia	Jurkat	-
	HSB2	-
NK cell leukemia	YT	-
Myeloid leukemia	HL-60	-
	K-562	-
	U-937	-

Reactivity of CD307a with PBL

Lymphocytes	-
Granulocytes	-
Monocytes	-

## **INFORMATION PROVIDED BY SUBMITTER**

### **Publications:**

Du X, Nagata S, Ise T, Stetler-Stevenson M, Pastan I. FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood. 2008 Jan 1;111(1):338-43.

**Patents:** No

**Licensed to a company and which one:** No

**Was it evaluated in a previous workshop?** No